External therapy of erosive and ulcerative skin lesions in chronic dermatoses

Background. Erosions and ulcers can be observed in many skin diseases. There were 20 patients with chronic dermatoses hospitalised at the Ural Research Institute of Dermatovenerology and Immunopathology (Ekaterinburg). All patients had chronic recurrent dermatoses with disease duration from 7 months to 9 years. During this observation the patients were prescribed standard systemic therapy in accordance with the severity of the skin process, provided by clinical recommendations, as well as external antiseptic agents of the latest generation – gel, which includes a modern antiseptic and surfactant.

Results. The article provides rationale for the use of the gel in external therapy of erosive and ulcerative skin defects in patients with chronic dermatoses. The article presents the results of efficacy and safety evaluation of using Prontosan gel during the topical treatment of patients with pemphigus vulgaris, chronic pyoderma and chronic non-healing trophic ulcers. The duration of the disease ranged from 7 months to 9 years. Clinical observation was conducted for 14 days of applying the medication, both in inpatient facilities and outpatient conditions. The gel proved to be highly effective in prompting the regression of perifocal edema and erythema, in reducing the exudation intensity and the amount of purulent discharge from ulcers and erosive defects. Application of the gel induces complete clearing of erosive and ulcerous surfaces from fibrin, promotes active marginal epithelization of skin defects, reduces total wound surface area by 24.6-66.3%, in particular due to the active forming of the granulation tissue. Evaluation of the dynamics of clinical symptoms such as burning sensation, itching and soreness, as well as monitoring of the dermatologic life quality index demonstrated complete regression of pain and other subjective sensations in patients, as well as almost complete restoration of the patients' quality of life (regression of DLQI by 69.5-77.6%).

1. Tabalbyev A. T., Ydyrysov I. T. Features of the drug Prontosan in the complex treatment of purulent wounds. Bulleten nauki i praktiki. 2023; 12 (9): 222-227. (In Russ.)

2. Vorobyev A. S., Levchik E. Yu. S. Solution and gel "prontosan" in local treatmentof different purulent wounds. URMZh. 2009; 1: 71-75. (In Russ.)

3. Encheva Yu. A., Kuznetsova M. V., Rubtsova E. A., Afanasievskaya E. V., Samartsev V. A. Chlorhexidine and "Prontosan" effect on biofilm formed by Staphylococcus aureus (in vitro study). Permskiy meditsinskii zhurnal 2015; 32 (1): 84-91. (In Russ.)

4. Пронтосан. Инструкция по применению. Prontosan. Patient information leaflet. (In Russ.)

5. Lewis K. Multidrug tolerance of biofilms and persister cells. Curr. Microbial. Immunol. 2008; 322: 107-131.

6. Krylov K. M., Krylov P. K. Modern opportunities of local treatment of burns. Ambulatornaya khirurgiya. 2010; 1 (37): 30-35. (In Russ.)

7. Grintsov A. G., Grintsova A. A., Karataeva K. O.Complex treatment of venous trophic ulcers of the lower extremities. Flebologiya, 2022; 2-2 (16): 35. (In Russ.)